Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALNY |
---|---|---|
09:32 ET | 5515 | 269.78 |
09:34 ET | 1400 | 269.72 |
09:36 ET | 1000 | 269.795 |
09:38 ET | 4519 | 270 |
09:39 ET | 1900 | 270.265 |
09:41 ET | 600 | 270.265 |
09:43 ET | 1400 | 270.455 |
09:45 ET | 1480 | 270.425 |
09:48 ET | 900 | 272.01 |
09:50 ET | 1900 | 271.195 |
09:52 ET | 3765 | 272.48 |
09:54 ET | 701 | 273.1444 |
09:56 ET | 3331 | 273.59 |
09:57 ET | 400 | 273.92 |
09:59 ET | 1300 | 274.32 |
10:01 ET | 5100 | 274.35 |
10:03 ET | 730 | 273.27 |
10:06 ET | 3074 | 273.39 |
10:08 ET | 200 | 273.25 |
10:10 ET | 700 | 273.14 |
10:12 ET | 1000 | 273.135 |
10:14 ET | 2050 | 273.4525 |
10:15 ET | 2595 | 273.0482 |
10:17 ET | 3726 | 272.85 |
10:19 ET | 1101 | 273.2 |
10:21 ET | 900 | 273.005 |
10:24 ET | 900 | 273.195 |
10:26 ET | 1078 | 272.965 |
10:28 ET | 100 | 273.005 |
10:30 ET | 300 | 273.13 |
10:32 ET | 654 | 273.29 |
10:33 ET | 1400 | 273.04 |
10:35 ET | 2300 | 272.97 |
10:37 ET | 1100 | 273.39 |
10:39 ET | 1900 | 273.41 |
10:42 ET | 500 | 273.63 |
10:44 ET | 382 | 273.5051 |
10:46 ET | 500 | 273.46 |
10:48 ET | 1300 | 273.405 |
10:50 ET | 200 | 273.33 |
10:51 ET | 1400 | 274.27 |
10:53 ET | 400 | 273.905 |
10:55 ET | 700 | 273.805 |
10:57 ET | 1300 | 273.805 |
11:00 ET | 3800 | 273.805 |
11:02 ET | 100 | 273.815 |
11:04 ET | 400 | 273.815 |
11:06 ET | 200 | 273.785 |
11:08 ET | 100 | 273.785 |
11:09 ET | 200 | 273.78 |
11:11 ET | 508 | 273.745 |
11:13 ET | 700 | 273.755 |
11:15 ET | 612 | 273.89 |
11:18 ET | 3002 | 275.32 |
11:20 ET | 1000 | 275.36 |
11:22 ET | 3164 | 276.305 |
11:24 ET | 4692 | 277.075 |
11:26 ET | 1600 | 276.94 |
11:27 ET | 700 | 276.915 |
11:29 ET | 535 | 277.02 |
11:31 ET | 15143 | 278.81 |
11:33 ET | 22367 | 280.1246 |
11:36 ET | 7196 | 281.445 |
11:38 ET | 5636 | 280.71 |
11:40 ET | 4763 | 280.56 |
11:42 ET | 8518 | 279.75 |
11:44 ET | 796 | 279.845 |
11:45 ET | 650 | 280.29 |
11:47 ET | 5613 | 279.74 |
11:49 ET | 3591 | 279.92 |
11:51 ET | 1264 | 280.3 |
11:54 ET | 3827 | 280.77 |
11:56 ET | 600 | 280.765 |
11:58 ET | 1373 | 280.47 |
12:00 ET | 2810 | 280.895 |
12:02 ET | 1681 | 281.01 |
12:03 ET | 804 | 280.96 |
12:05 ET | 2525 | 280.18 |
12:07 ET | 1225 | 280.08 |
12:09 ET | 423 | 279.925 |
12:12 ET | 904 | 280.26 |
12:14 ET | 6836 | 281.605 |
12:16 ET | 410 | 282 |
12:18 ET | 4539 | 282.45 |
12:20 ET | 700 | 281.975 |
12:21 ET | 5868 | 280.91 |
12:23 ET | 134 | 281.24 |
12:25 ET | 300 | 280.84 |
12:27 ET | 100 | 280.84 |
12:30 ET | 4329 | 281.425 |
12:32 ET | 400 | 281.245 |
12:34 ET | 802 | 280.975 |
12:36 ET | 1100 | 280.68 |
12:38 ET | 581 | 280.68 |
12:39 ET | 2797 | 280.615 |
12:41 ET | 1777 | 280.575 |
12:43 ET | 1366 | 280.575 |
12:45 ET | 2377 | 279.74 |
12:48 ET | 2125 | 279.53 |
12:50 ET | 1200 | 279.005 |
12:52 ET | 7810 | 278.9 |
12:54 ET | 700 | 278.78 |
12:56 ET | 1123 | 278.71 |
12:57 ET | 1254 | 278.6 |
12:59 ET | 3794 | 278.42 |
01:01 ET | 400 | 278.3 |
01:03 ET | 1720 | 278.505 |
01:06 ET | 501 | 278.325 |
01:08 ET | 2040 | 277.935 |
01:10 ET | 784 | 277.99 |
01:12 ET | 653 | 277.067 |
01:14 ET | 2312 | 277.47 |
01:15 ET | 400 | 277.29 |
01:17 ET | 1200 | 277.295 |
01:19 ET | 300 | 277.05 |
01:21 ET | 1689 | 276.95 |
01:24 ET | 1885 | 276.76 |
01:26 ET | 5058 | 276.63 |
01:28 ET | 300 | 276.48 |
01:30 ET | 1250 | 276.7925 |
01:32 ET | 1100 | 275.77 |
01:33 ET | 1053 | 276.25 |
01:35 ET | 886 | 276.165 |
01:37 ET | 500 | 276.1 |
01:39 ET | 2293 | 276.415 |
01:42 ET | 3392 | 277.06 |
01:44 ET | 500 | 277.16 |
01:46 ET | 1004 | 277.3 |
01:48 ET | 100 | 277.065 |
01:50 ET | 1150 | 277 |
01:51 ET | 7850 | 276.985 |
01:53 ET | 400 | 277 |
01:55 ET | 5842 | 276.92 |
01:57 ET | 3200 | 277.17 |
02:00 ET | 100 | 277.18 |
02:02 ET | 1064 | 277.74 |
02:04 ET | 1565 | 277.11 |
02:06 ET | 400 | 277.31 |
02:08 ET | 300 | 277.06 |
02:09 ET | 1077 | 277.1 |
02:11 ET | 100 | 277.12 |
02:13 ET | 100 | 277.35 |
02:15 ET | 2875 | 277.14 |
02:18 ET | 100 | 277.0988 |
02:20 ET | 1100 | 277.115 |
02:22 ET | 600 | 277 |
02:24 ET | 3900 | 277.08 |
02:26 ET | 100 | 277.065 |
02:27 ET | 1500 | 277.175 |
02:31 ET | 600 | 277.0626 |
02:36 ET | 100 | 277.09 |
02:38 ET | 1100 | 277.195 |
02:40 ET | 100 | 277.235 |
02:42 ET | 800 | 277.195 |
02:45 ET | 1745 | 277 |
02:47 ET | 858 | 277.215 |
02:49 ET | 300 | 277.23 |
02:51 ET | 100 | 277.22 |
02:56 ET | 400 | 277.185 |
02:58 ET | 100 | 277.16 |
03:00 ET | 10242 | 277 |
03:02 ET | 1800 | 277.22 |
03:03 ET | 1404 | 277.47 |
03:05 ET | 540 | 277.305 |
03:07 ET | 100 | 277.345 |
03:14 ET | 200 | 277.32 |
03:16 ET | 2125 | 278.07 |
03:18 ET | 900 | 278.01 |
03:20 ET | 1345 | 278.83 |
03:21 ET | 301 | 278.9033 |
03:23 ET | 148 | 279.1599 |
03:25 ET | 600 | 278.72 |
03:27 ET | 3599 | 279.09 |
03:30 ET | 200 | 279.055 |
03:32 ET | 250 | 278.865 |
03:34 ET | 4100 | 279 |
03:36 ET | 4235 | 279 |
03:38 ET | 1300 | 279.05 |
03:39 ET | 1500 | 278.98 |
03:41 ET | 1463 | 278.9475 |
03:43 ET | 7555 | 279 |
03:45 ET | 9669 | 279.46 |
03:48 ET | 716 | 278.61 |
03:50 ET | 2039 | 278.965 |
03:52 ET | 2400 | 278.92 |
03:54 ET | 1227 | 278.93 |
03:56 ET | 12112 | 277.765 |
03:57 ET | 9149 | 278.31 |
03:59 ET | 126318 | 278.62 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alnylam Pharmaceuticals Inc | 34.8B | -443.3x | --- |
Royalty Pharma PLC | 16.4B | 18.3x | +1.83% |
Endo Inc | 1.8B | 0.4x | --- |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Amneal Pharmaceuticals Inc | 2.7B | -13.6x | --- |
Prestige Consumer Healthcare Inc | 3.4B | 16.7x | --- |
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.8B |
---|---|
Revenue (TTM) | $2.3B |
Shares Outstanding | 128.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $-0.63 |
Book Value | $-1.75 |
P/E Ratio | -443.3x |
Price/Sales (TTM) | 14.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 4.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.